Adverse effects of immunosuppression in pediatric solid organ transplantation

Pediatric Drugs

Volumn 12, Issue 1, 2010, Pages 35-49

  Schonder, Kristine S ^a,b   Mazariegos, George V ^c,d   Weber, Robert J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Children; Ciclosporin, adverse reactions; Corticosteroids, adverse reactions; Diabetes mellitus; Dyslipidaemias; Growth disorders; Hypertension; Immunosuppressants, adverse reactions; Infections; Neurologic manifestations

Indexed keywords

ACICLOVIR; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; BASILIXIMAB; BENZOYL PEROXIDE; CHICKENPOX VACCINE; CHOLESTEROL; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; HUMAN GROWTH HORMONE; MEASLES MUMPS RUBELLA VACCINE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PRAVASTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; VALACICLOVIR; VALGANCICLOVIR;

ACNE; ANOREXIA; BEHAVIOR DISORDER; BLOOD PRESSURE MONITORING; BODY HEIGHT; BONE MINERALIZATION; BRAIN RADIATION; CANCER RISK; CARDIAC GRAFT REJECTION; CAUSE OF DEATH; CHICKENPOX; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; COGNITIVE DEVELOPMENT; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; EPSTEIN BARR VIRUS; FOLLICULITIS; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; GROWTH RETARDATION; HALLUCINATION; HEARING LOSS; HEART TRANSPLANTATION; HEMOPERFUSION; HERPES VIRUS; HIRSUTISM; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; HYGIENE; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; INFECTION RISK; INSOMNIA; INTESTINE GRAFT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LANGUAGE DISABILITY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MEASLES; MEDLINE; MONONUCLEOSIS; MORBIDITY; MUMPS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NUTRITIONAL STATUS; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PEDIATRIC SURGERY; POLYMERASE CHAIN REACTION; POSTTRANSPLANT DIABETES MELLITUS; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PSYCHOSOCIAL DEVELOPMENT; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; RISK FACTOR; RISK REDUCTION; RUBELLA; SIDE EFFECT; STUPOR; SURVIVAL TIME; TINEA VERSICOLOR; TRIACYLGLYCEROL BLOOD LEVEL; VACCINATION; VASCULAR DISEASE; VERRUCA VULGARIS;

ANTI-INFECTIVE AGENTS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD DEVELOPMENT; COMMUNICABLE DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; LYMPHOPROLIFERATIVE DISORDERS; NEOPLASMS; NERVOUS SYSTEM DISEASES; ORGAN TRANSPLANTATION; PEDIATRICS; QUALITY OF LIFE; RECOMBINANT PROTEINS;

EID: 73849141204     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11316180-000000000-00000     Document Type: Review

References (120)

1. North American Pediatric Renal Transplant Cooperative Study 2007 Annual Report. Rockville (MD); NAPRTCS, 2007
2. Feng S, Si M, Taranto SE, et al. Trends over a decade of liver pediatric transplantation in the United States. Liver Transplant 2006 Apr; 12 (4): 578-584
3. GrantD,Abu-ElmagdK,Reyes J, et al. 2003 report of the intestine transplant registry: a new era has dawned. Ann Surg 2005 Apr; 241 (4): 607-613
4. Boucek MM, Aurora P, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report - 2007. J Heart Lung Transplant 2007 Aug; 26 (8): 796-807 (Pubitemid 47199083)
5. Aurora P, Boucek MM, Christie J, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric lung and heart/lung transplantation report - 2007. JHeart Lung Transplant 2007 Dec; 26 (12): 1223-1228 (Pubitemid 350256978)
6. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383
7. Fridell JA, Jain A, Reyes J, et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. Transplantation 2002 Dec 27; 74: 1721-1724
8. Dharnidharka VR, Stablein DM, Harmon WE. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004; 4: 384-389
9. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.Ablinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996 Apr 15; 61 (7): 1029-1037
10. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232
11. European Mycophenolate Mofetil Cooperative Study Group. Placebocontrolled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325
12. Renoult E, Buteau C, Lamarre V, et al. Infectious risk in pediatric organ transplant recipients: is it increased with the new immunosuppressive agents? Pediatr Transplant 2005; 9: 470-479
13. Rand EB, Olthoff KM. Overview of pediatric liver transplantation. Gastroenterol Clin N Am 2003; 32: 913-929
14. Fishman JA, Rubin RH. Infections in organ transplant recipients. N Engl J Med 1998; 338: 1740-1751
15. Fishman JA. Infections in solid organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614
16. Humar A, Gillingham KJ, Payne WD, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999 Dec 27; 68 (12): 1879-1883 (Pubitemid 30027341)
17. Evans PC, Soin A, Wreghitt TG, et al. As association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000 Jan 15; 69 (1): 30-35
18. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to cytomegalovirus. Am Heart J 1999 Nov; 138 (5 Pt 2): S469-72
19. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Pediatr Drugs 2005; 7 (1): 55-65
20. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006 Feb; 10 (1): 78-82
21. Kasiske BL, Zeier MG, for the KDIGO Working Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl. 3: S1-155
22. Humar A, Hébert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein- Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006 Mar 27; 81 (6): 856-861
23. Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. JAMA 2006 Dec 20; 296 (23): 2823-2831
24. Tenderich G, Deyerling W, Schulz U, et al. Malignant neoplastic disorders following long-term immunosuppression after orthotopic heart transplantation. Transplant Proc 2001; 33: 3653-3655
25. Kasiske BL, Snyder JJ, Gilberston DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
26. Euvrard S, Kanitakis J, Cochat P, et al. Skin cancers following pediatric organ transplantation. Dermatol Surg 2004 Apr; 30 (4 Pt 2): 216-221
27. Sato K, Ogawa K, Onumata O, et al. Cause of death in renal transplant patients: a comparison between azathioprine and ciclosporin. Surg Today 2001; 31: 681-687
28. Abu-Elmagd KM, Zak M, Stamos JM, et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation 2004 Jun 15; 77: 1719-1725
29. Reyes J, Bueno J, Kocoshis S, et al. Current status of intestinal transplantation in children. J Pediatr Surg 1998 Feb; 33 (2): 243-254
30. Gao SZ, Chaparro SV, PerlrothM, et al. Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University. J Heart Lung Transplant 2003 May; 22 (5): 505-514
31. Lee TC, Savoldo B, Barshes NR, et al. Use of cytokine polymorphisms and Epstein-Barr viral load to predict development of post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Clin Transplant 2006; 20: 389-393
32. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001 Apr 27; 71: 1065-1068
33. Bond G, Felmet K, Jaffe R, et al. Intestinal and multivisceral transplantation. In: Nichols D, editor. Rogers' textbook of pediatric intensive care. Philadelphia (PA): Lippincott Williams & Wilkins, 2008: 1550-1561
34. Wadowsky RM, Laus S, Green M, et al. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes in competitive PCR. J Clin Microbiol 2003; 41 (11): 5245-5249
35. Kirk AD, Cherikh WS, Rina M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619-2625
36. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival and patient survival after primary kidney transplantation. Transplantation 2003 Nov 15; 76: 1289-1293
37. Boratyń ska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders [letter]. Transpl Int 2008 Jun; 21 (6): 605-608
38. Vaysberg M, Balatoni CE, Nepomuceno RR, et al. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation 2007 Apr 27; 83: 1114-1121
39. Tai CC, Curtis JL, Szmuszkovica JR, et al. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality. J Pediatr Surg 2008; 43: 2174-2177
40. Mazariegos G. Withdrawal of immunosuppression in liver transplantation: lessons learned from PTLD. Pediatr Transplant 2004; 8 (3): 210-213
41. Green M, Webber S. Posttransplantation lymphoproliferative disorders. Pediatr Clin North Am 2003; 50 (6): 1471-1491
42. Gross TG, Bucubalas JC, Park JR, et al. Low-dose chemotherapy for Epstein- Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005; 23 (27): 6481-6488
43. Saland JM. Osseous complications of pediatric transplantation. Pediatr Transplant 2004; 8: 400-415
44. Alonso EM. Growth and developmental considerations in pediatric liver transplantation. Liver Transplant 2008; 14: 585-591
45. Hathout EH, Chinnock RE. Growth after heart transplantation [editorial]. Pediatr Transplant 2004; 8: 97-100
46. Fine RN. Growth following solid-organ transplantation. Pediatr Transplant 2002; 6: 47-52
47. Vasudevan A, Phadke K. Growth in pediatric renal transplant recipients. Transplant Proc 2007; 39: 753-755
48. Englund MS, Tydén G, Wikstad I, et al. Growth impairment at renal transplantation: a determinant of growth and final height. Pediatr Transplant 2003; 7: 192-199
49. Lacaille F, Vass N, Sauvat F, et al. Long-term outcome, growth and digestive fucntion in children 2 to 18 years after intestinal transplantation. Gut 2008; 57: 455-461
50. Fine RN, Tejani A. Growth following renal transplantation in children. Transplant Proc 1998; 30: 1959-1960
51. McDiarmid SV, Gornbein JA, DeSilva PJ, et al. Factors affecting growth after pediatric liver transplantation. Transplantation 1999 Feb 15; 67 (3): 404-411
52. Urbach AH, Gartner JC,Malatack JJ, et al. Linear growth following pediatric liver transplantation. Am J Dis Child 1987 May; 141 (5): 547-549
53. Reid IR. Glucocorticoid osteoporosis: mechanisms and management. Eur J Endocrinol 1997; 137: 209-217
54. Sarna S, Hoppu K, Neuvonen PJ, et al. Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. J Clin Endocrinol Metab 1997; 82 (1): 75-77
55. Falkenstein K, Dunn S. Growth acceleration on cyclosporine monotherapy after liver transplantation in children. Transplant Proc 1998; 30: 1969-1972
56. Cohen A, Addonizio LJ, Softness B, et al. Growth and skeletal maturation after pediatric cardiac transplantation. Pediatr Transplant 2004; 8: 126-135
57. Clot JP, Crosnier H, Guest G, et al. Effects of growth hormone on growth factors after renal transplantation. Pediatr Nephrol 2001; 16: 397-403
58. Sarna S, SipliläI, Rönnholm K, et al. Recombinant human growth hormone improves growth in children receiving glucocorticoid treatment after liver transplantation. J Clin Endocrin Metab 1996; 81: 1476-1482
59. Mital S, Andron A, Lamour JM, et al. Effects of growth hormone therapy in children after cardiac transplantation. J Heart Lung Transplant 2006; 25 (7): 772-777
60. Kennard B, Stewart S, Phelan-McAuliffe D, et al. Academic outcome in longterm survivors of pediatric liver transplantation. J Dev Behav Pediatr 1999 Feb; 20 (1): 17-23
61. Siirtola A, Antikainen M, Ala-Houhala M, et al. Insulin resistance, LDL particle size, and LDL susceptibility to oxidation in pediatric kidney and liver recipients. Kidney Int 2005; 67: 2046-2055
62. Sorof JM, Sullivan EK, TejaniA, et al. Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study Report. J Am Soc Nephrol 1999; 10: 1324-1330 (Pubitemid 29246999)
63. Roche SL, Kaufmann J, Dipchand AI, et al. Hypertension after pediatric heart transplantation is primarily associated with immunosuppressive regimen. J Heart Lung Transplant 2008 May; 27: 501-507
64. Avitzur Y, De Luca E, Cantos M, et al. Health status ten years after pediatric liver transplantation: looking beyond the graft. Transplantation 2004; 78: 566-573
65. Seeman T,S imková E, Kreisinger J, et al. Improved control of hypertension in children after renal transplantation: results of a two-yr interventional trial. Pediatr Transplant 2007; 11: 491-497
66. Ohkubo T, Hozawa A, Yamaguchi J, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens 2002; 20 (11): 2183-2189
67. Ferraris JR, Ghezzi L, Waisman G, et al. Potential cardiovascular risk factors in paediatric renal transplant recipients. Pediatr Nephrol 2006; 21: 119-125
68. Büscher R, Vester U, Wingen AM, et al. Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients. Pediatr Nephrol 2004; 19: 1201-1211
69. Nagasako SS, Nogueira PCK, Machado PGP, et al. Risk factors for hypertension 3 years after renal transplantation in children. Pediatr Nephrol 2007; 22: 1363-1368
70. Kavey REW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients. J Cardiovasc Nurs 2007 May/Jun; 22 (3): 218-253
71. Seeman T,S imková E, Kreisinger J, et al. Control of hypertension in children after renal transplantation. Pediatr Transplant 2006; 10: 316-322
72. Tejani A, Sullivan K, Alexander S, et al. Posttransplant deaths and factors that influence the mortality rate in North American children. Transplantation 1994; 57 (4): 547-553
73. Valavi E, Otukesh H, Sereshtehnejad SM, et al. Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy. Pediatr Transplant 2008; 12: 748-754
74. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2003; 23: S187-93
75. Siirtola A, Antikainen M, Ala-Houhala M, et al. Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation. Transpl Int 2004; 17: 109-119
76. Law YM, Yim R, Agatisa P, et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 2006 Mar; 25 (3): 276-282
77. Penson MG, Winter WB, Fricker FJ, et al. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. J Heart Lung Transplant 1999 Jul; 18 (7): 707-713
78. Soylu A, Kavukçu S,Türkmen MA, et al. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods. Transplant Proc 2006; 38 (5): 1286-1289
79. Gupta P, Kaufman S, Fisbhein TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant 2005; 9: 269-276
80. Argent E, Kainter G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 2003; 7: 38-42
81. Butani L. Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transplant 2005; 9: 746-753
82. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipdemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001 Jun; 20 (6): 611-618
83. Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185
84. Paolillo JA, Boyle GJ, Law YM, et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation 2001 Jan 27; 71 (2): 252-256
85. Al-Urzi A, Stablein DM, Cohn RA. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 72 (6): 1020-1024
86. Bartosh SM, Leverson G, Robillard D, et al. Long-term outcomes in pediatric renal transplant recipients who survive into adulthood. Transplantation 2003 Oct 27; 76 (8): 1195-1200
87. Bodziak KA, Hricik DE. New-onset diabetes mellitus after solid organ transplantation. Transpl Int 2008; 22: 519-530
88. Oetjen E, Raun D, Seimesche S, et al. Inhibition of human insulin gene transcription by the immunosuppressive drugs cyclosporine A and tacrolimus in primary, mature islets of transgenic mice. Molec Pharmacol 2003 Jun; 63 (6): 1289-1295
89. Hathout EH, Chinnock RE, Johnston JK, et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant 2003; 3: 994-998
90. Greenspan LC, Gitelman SE, Leung MA, et al. Increased incidence in posttransplant diabetes mellitus in children: a case-control analysis. Pediatr Nephrol 2002; 17: 1-5
91. Johnson O, Rose CL, Webster AC, et al. Sirolimus is associated with newonset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418
92. Butani L, Makker SP. Conversion from tacrolimus to neural for postrenal transplant diabetes. Pediatr Nephrol 2000; 15: 176-178
93. Alonso EM. Long-term renal function in pediatric liver and heart recipients. Pediatr Transplant 2004; 8: 381-385
94. Di Filippo S, Cochat P, Bozio A. The challenge of renal function in heart transplant children. Pediatr Nephrol 2007; 22: 333-342
95. Pradhan M, Leonard MG, Bridges ND, et al. Decline in renal function following thoracic organ transplantation in children. Am J Transplant 2002; 2: 652-657
96. Hornung TX, de Goede CGEL, O'Brien C, et al. Renal function after pediatric cardiac transplantation: the effect of early cyclosporin dosage. Pediatrics 2001 Jun; 107 (6): 1346-1350
97. Arora-Gupta N, Davies P, McKiernan P, et al. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004; 8: 145-150
98. English RE, Pophal SA, Bacanu SA, et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric hearttransplant recipients. Am J Transplant 2002 Sep; 2 (8): 769-773
99. Vogler C, Wang Y, Brink DS, et al. Renal pathology in the pediatric transplant patient. Adv Anat Pathol 2007 May; 14 (3): 202-216
100. Nankivell BJ, Borrows RJ, Fung CLS, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004 Aug 27; 78 (4): 557-565
101. Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003 Nov 15; 76 (9): 1326-1330
102. Ferraris JR, Duca P, Prigoshin N, et al. Mycophenolate mofetil and reduced doses of cyclosporine in pediatric liver transplantation with chronic renal dysfunction: changes in the immune responses. Pediatr Transplant 2004; 8: 545-549
103. Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005 May 27; 79 (10): 1405-1410
104. Sindhi R, Webber S, Venkataramanan R, et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 2001 Sept 15; 72 (5): 851-855
105. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation: results from the U.S. Multicenter Trial. Transplantation 1995 Feb 27; 59 (4): 530-536
106. Kemper MJ, Spartà G, Laube GF, et al. Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation. Clin Transplant 2003; 17: 130-134
107. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13: 313-326
108. Emre S,Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transpl Int 2000; 13: 73-78
109. Chabria D, Weintraub RG, Kilpatrick NM. Mechanisms and management of gingival overgrowth in paediatric transplant recipients: a review. Int J Paediatr Dent 2003; 13: 220-229
110. Wirnsberger GH, Pfranger R, Maurio A, et al. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. Transplant Proc 1998; 30: 2117-2119
111. Busque S, Demers P, St-Louis G, et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc 1998; 30: 1247-1248
112. Reyes J, Jain A, Mazariegos G, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 2000 June 27; 69 (12): 2573-2580
113. Fortina AB, Piaserico S, Alaibac M, et al. Skin disorders in patients transplanted in childhood. Transpl Int 2005; 18: 360-365
114. Euvrard S, Kanitakis J, Cochat P, et al. Skin diseases in children with organ transplants. J Am Acad Dermatol 2001; 44 (6): 932-939 (Pubitemid 32493442)
115. Navaneethan SD, Sankarasubbaiyan S, Gross MD, et al. Tacrolimusassociated hypomagnesemia in renal transplant recipients. Transplant Proc 2006; 38: 1320-1322
116. Miura K, Nakatani T, Asai T, et al. Role of hypomagnesemia in chronic cyclsoporine nephropathy. Transplantation 2002 Feb 15; 73 (3): 340-347
117. Holzmacher R, Kendziorski C, Hofman RM, et al. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 2005; 20: 1456-1462
118. Trompeter R, Filler G, Webb NJA, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141-149
119. Thakur V, Kumar R, Dhawan IK. Correlation between serum magnesium and blood cyclosporine A concentrations in renal transplant recipients. Ann Clin Biochem 2002; 39: 70-72
120. Aker S, Heering P, Kinne-Saffran E, et al. Different effects of cyclsoporine A and FK506 on potassium transport systems in MDCK cells. Exp Nephrol 2001; 9 (5): 332-340